NCT00030537View on ClinicalTrials.gov

Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 2001

Study Completion Date

March 31, 2003

Conditions
Breast Cancer
Interventions
DRUG

erlotinib hydrochloride

Trial Locations (2)

20889-5101

Center for Cancer Research, Bethesda

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00030537 - Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter